Pharma Summits Patent Cliff in 2012: Total $290B at Risk
By Nuala Moran
Wednesday, June 20, 2012
BOSTON 2012 may be the year that the patent cliff reaches its height with $33 billion of sales at risk but the impact of loss of exclusivity will continue to reverberate across the decade, with more than $290 billion of prescription drugs sales due to be exposed to generic competition between now and 2018.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.